Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

AIM: To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID‐19 outpatients. METHODS: In this open‐label, first‐in‐patient study a single dose of either 225 mg (n = 6) or 600 mg (n = 6) of ensovibep was administered intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Prins, Manon L. M., van der Plas, Johan L., Vissers, Maurits F. J. M., Berends, Cécile L., Tresch, Gaby, Soergel, Marianne, Fernández, Elena, van den Berge, Nikita, Duijsings, Daniël, Zitt, Christof, Stavropoulou, Vaia, Zimmermann, Maya, Drake, Roxana F., Burggraaf, Jacobus, Groeneveld, Geert H., Kamerling, Ingrid M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875039/
https://www.ncbi.nlm.nih.gov/pubmed/36214216
http://dx.doi.org/10.1111/bcp.15560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875039/
https://www.ncbi.nlm.nih.gov/pubmed/36214216
http://dx.doi.org/10.1111/bcp.15560

Ejemplares similares